NOTICE TO READER:
As with all of our Q&A sessions, we were not approached or requested to undertake the Q&A but rather we approach
those companies that we feel the timing is right. No compensation of any kind or in any form is every offered, requested, expected, or received.
Quick Summary of Key Metrics as at November 3, 2017
Shares issued and Outstanding: (www.thecse.com)
Current Share Price:
CCIM: Hello and right out of the gate I would like to take this moment to first thank you for your time. The purpose of this discussion is to bring a greater investor awareness of Maricann.
MARI: Thank you for this opportunity to share the Maricann story with your readers.
CCIM: How long have you been with Maricann and what is your position and duties?
MARI: I have been with Maricann for over a year now. I am currently both the CEO and a Director of the company.
CCIM: For the benefit of our readers, walk me through your two sites and the nature of the Health Canada issued licences at each location.
MARI: Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 217,000 sq. ft. (20,159 sq. m) build out, to support existing and future patient growth.
Louis Kyron: CCIM
Ben Ward: MARI
CSE:MARI; OTCQB:MRRCF; FRA:75M
234